Sydney M Crago

Alan Franklin, MD, PhD, FASRS, spoke about his presentation, "Intraoperative Fluorescein Angiography Reduces the Rate of Postoperative Vitreous Hemorrhage" at this year's American Society of Retina Specialists (ASRS) meeting in Stockholm, Sweden.

Ashkan Abbey, MD, spoke about his presentation on the CALM registry study, the 36-month outcomes of real-world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.

Sally S. Ong, MD, spoke about her study on the impact of individual and neighborhood-level social determinants of health on vision and foveal status at presentation in patients with rhegmatogenous retinal detachments at the annual ASRS meeting in Stockholm, Sweden.

John T. Thompson, MD, spoke about his presentation, "Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling" at the annual ASRS meeting in Stockholm, Sweden.

Michael Singer, MD, presented 100-week results from the RESTORE trial and shares key takeaways from his presentation at this year's American Society of Retina Specialists (ASRS) meeting.

Patrick C. Staropoli, MD, discussed his presentation on the clinical characterization of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa while attending the annual ASRS meeting in Stockholm, Sweden.

Stephen Russell, MD, discussed his presentation on safety and durability of voretigene neparvovec-rzyl for biallelic RPE65 at the annual ASRS meeting in Stockholm, Sweden.

Charles Wykoff, MD, PhD, gives an insight into first-time data from the phase 2, LUNA trial looking at Ixo-Vec at the annual ASRS meeting in Stockholm, Sweden.

Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden.

Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.

Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals Encapsulated Cell Therapy platform for the potential treatment of Macular Telangiectasia Type 2, with a projected PDUFA goal date from the FDA at the annual ASRS meeting in Stockholm, Sweden.

Jennifer Lim, MD, FARVO, FASRS, gives an update on the phase 2 DAVIO 2 trial comparing EYP-1901 with aflibercept at the annual ASRS meeting in Stockholm, Sweden.

Richard B. Rosen, MD, from the New York Eye and Ear Infirmary of Mount Sinai discussed his presentation on sickle cell retinopathy and the measurement with dynamic OCT angiography and quad-fusion adaptive optics imaging at the annual ASRS meeting in Stockholm, Sweden.

Paolo Antonio Silva, MD, discusses his presentation on diabetic retinopathy lesion types and distribution on ultra-widefield imaging and the risk for disease worsening over time at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Danny A. Mammo, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on intraocular pressure outcomes following suprachoroidal triamcinolone acetonide in patients with glaucoma at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Rishi P. Singh, MD, sat down with Sydney Crago, Editor of Modern Retina, to discuss his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Durga Borkar, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss her presentation on Fas inhibition with ONL1204 for the Treatment of Geographic Atrophy and the first-time results From a Phase 1b study at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Theodore Lang, MD, MS, sat down to discuss his presentation on the FARETINA-DME Study at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Carl Danzig, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on the 72-Week results from the Phase 3 BALATON and COMINO trials at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Srinivas Sai Kondapalli, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on the predictive role of outer retinal tubulations in lesion growth for subfoveal and non subfoveal geographic atrophy at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, spoke with attendees, who shared which topics they are most looking forward to discussing at the American Society of Retina Specialists (ASRS) meeting held in Stockholm, Sweden.

Attendees shared which topics they are most looking forward to discussing at the American Society of Retina Specialists (ASRS) meeting held in Stockholm, Sweden.

Jennifer Lim, MD, FARVO, FASRS, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss her presentation on differential artery-vein analysis in eyes with diabetic retinopathy and improvements on the OCTA classification using artificial intelligence at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

The ASRS annual meeting will take place in Stockholm, Sweden on July 16-20, 2024. Several major updates are already anticipated at the event.

Data can clear a path to trends and strategies to meet patients’ needs

In a conversation with the Eye Care Network at ARVO, Osamah Saeedi, MD, MS, Associate Professor of Ophthalmology, Director of Clinical Research and Director of the Glaucoma Division at the University of Maryland School of Medicine, explained the key findings from his poster.

More companies have released information on presentations related to their pipelines and new data at the ARVO 2024 conference.

The tool shows disease progression and vision loss simulations for multiple diseases such as AMD, XLRP, and achromatopsia

Akari Therapeutics, Ocuphire Pharma, and PharmAbcine are among the companies that have shared their plans for presentations at the ARVO annual conference in Seattle, Washington.